GlassScriptPhysician profile
Assem Houssein
NPI 1700865722
$6,811.67
in general payments reported to CMS, 2019-2025
25 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,331 · 2020: $591 · 2021: $1,204 · 2022: $1,366 · 2023: $483 · 2024: $704 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,318.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,403.36 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Xeris Pharmaceuticals, INC. | $896.93 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $623.26 | 2021-2025 | Omnipod |
| Dexcom, INC. | $558.11 | 2019-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $404.47 | 2019-2025 | Mounjaro, Zepbound, Humulin |
| Astrazeneca Pharmaceuticals LP | $380.66 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $324.99 | 2019-2022 | |
| Abbott Laboratories | $189.11 | 2020-2024 | Freestyle Libre 3 |
| Amgen INC. | $152.03 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $145.42 | 2019-2025 | |
| Medtronic, INC. | $144.09 | 2021-2024 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Corcept Therapeutics | $130.36 | 2019-2025 | Korlym |
| Medtronic Minimed, INC. | $74.25 | 2019-2020 | |
| Horizon Therapeutics Plc | $62.83 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.98 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $53.03 | 2022 | |
| Radius Health, INC. | $36.10 | 2022 | |
| Tandem Diabetes Care, INC. | $35.95 | 2020-2022 | |
| Abbvie INC. | $32.63 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.96 | 2019-2022 | |
| Antares Pharma, INC. | $17.79 | 2019 | |
| Ibsa Pharma INC. | $15.77 | 2022 | |
| Esperion Therapeutics, INC. | $14.77 | 2021 | |
| Sequel Med Tech, LLC | $13.83 | 2025 | Twiist |
| Amarin Pharma, INC. | $11.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Assem Houssein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.